Long term outcomes of intravitreous aflibercept injections for agerelated macular degeneration

Long term outcomes of intravitreous aflibercept injections for agerelated macular degeneration - Long term outcomes of IAI for AMD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000024419

Enrollment

120

Registered

2016-10-15

Start date

2012-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-related macular degeneration

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who diagnosed wet AMD.

Exclusion criteria

Exclusion criteria: Patients who diagnosed central serous chorioretinopathy CSC or any other vitreo-retinal diseases.

Design outcomes

Primary

Measure	Time frame
Best corrected visual acuity, retinal structure, choroidal structure, and adverse event.	—

Secondary

Measure	Time frame
Number of IAI.	—

Countries

Japan

Contacts

Public ContactKei Takayama

Nagoya University Graduate School of Medicine Department of Ophthalmology Protective care for Sensory Disorders

keitaka1234@med.nagoya-u.ac.jp052-744-2275

Outcome results